Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
As of close of business last night, Harvard Bioscience Inc’s stock clocked out at $0.64, up 1.17% from its previous closing price of $0.63. In other words, the price has increased by $1.17 from its previous closing price. On the day, 1.56 million shares were traded. HBIO stock price reached its highest trading level at $0.7 during the session, while it also had its lowest trading level at $0.621.
Ratios:
To gain a deeper understanding of HBIO’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.20 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 4.24. For the most recent quarter (mrq), Quick Ratio is recorded 0.41 and its Current Ratio is at 0.81. In the meantime, Its Debt-to-Equity ratio is 3.04 whereas as Long-Term Debt/Eq ratio is at 0.52.
On March 10, 2023, The Benchmark Company Upgraded its rating to Buy which previously was Speculative Buy and also upped its target price recommendation from $3 to $4.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HBIO now has a Market Capitalization of 28633518 and an Enterprise Value of 64601520. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.33 while its Price-to-Book (P/B) ratio in mrq is 2.04. Its current Enterprise Value per Revenue stands at 0.739 whereas that against EBITDA is 12.954.
Stock Price History:
The Beta on a monthly basis for HBIO is 1.45, which has changed by -0.7123288 over the last 52 weeks, in comparison to a change of 0.09654534 over the same period for the S&P500. Over the past 52 weeks, HBIO has reached a high of $2.40, while it has fallen to a 52-week low of $0.28. The 50-Day Moving Average of the stock is 29.84%, while the 200-Day Moving Average is calculated to be 20.90%.
Shares Statistics:
It appears that HBIO traded 6.34M shares on average per day over the past three months and 1471860 shares per day over the past ten days. A total of 44.58M shares are outstanding, with a floating share count of 38.25M. Insiders hold about 14.20% of the company’s shares, while institutions hold 36.00% stake in the company. Shares short for HBIO as of 1761868800 were 7047412 with a Short Ratio of 1.11, compared to 1759190400 on 681364. Therefore, it implies a Short% of Shares Outstanding of 7047412 and a Short% of Float of 17.09.
Earnings Estimates
Harvard Bioscience Inc (HBIO) is presently subject to a detailed evaluation by 2.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.0, with high estimates of $0.01 and low estimates of -$0.02.
Analysts are recommending an EPS of between $0.04 and $0.02 for the fiscal current year, implying an average EPS of $0.03. EPS for the following year is $0.09, with 2.0 analysts recommending between $0.13 and $0.06.
Revenue Estimates
In. The current quarter, 2 analysts expect revenue to total $23.1M. It ranges from a high estimate of $23.4M to a low estimate of $22.8M. As of. The current estimate, Harvard Bioscience Inc’s year-ago sales were $24.56MFor the next quarter, 2 analysts are estimating revenue of $21.25M. There is a high estimate of $21.7M for the next quarter, whereas the lowest estimate is $20.8M.
A total of 2 analysts have provided revenue estimates for HBIO’s current fiscal year. The highest revenue estimate was $86.2M, while the lowest revenue estimate was $85.6M, resulting in an average revenue estimate of $85.9M. In the same quarter a year ago, actual revenue was $94.14MBased on 2 analysts’ estimates, the company’s revenue will be $92.1M in the next fiscal year. The high estimate is $95.6M and the low estimate is $88.6M.
